Citigroup Issues Pessimistic Forecast for BioNTech (NASDAQ:BNTX) Stock Price

BioNTech (NASDAQ:BNTX) had its price objective lowered by research analysts at Citigroup from $145.00 to $130.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 44.28% from the stock’s previous close.

BNTX has been the subject of several other reports. TD Cowen dropped their target price on BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a report on Wednesday. BMO Capital Markets lowered their target price on BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a report on Wednesday. The Goldman Sachs Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a report on Tuesday. Finally, Jefferies Financial Group dropped their price objective on BioNTech from $151.00 to $138.00 and set a “buy” rating on the stock in a report on Tuesday. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $133.73.

BioNTech Stock Down 0.8%

BNTX stock opened at $90.10 on Wednesday. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00. The firm has a 50-day simple moving average of $106.54 and a 200-day simple moving average of $102.66. The company has a quick ratio of 7.02, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $20.29 billion, a P/E ratio of -17.19 and a beta of 1.51.

Hedge Funds Weigh In On BioNTech

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC increased its position in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG bought a new position in shares of BioNTech in the 4th quarter worth about $29,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the period. Financial Consulate Inc. bought a new stake in shares of BioNTech during the 3rd quarter valued at about $36,000. Finally, Huntington National Bank grew its position in shares of BioNTech by 1,266.7% during the 3rd quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech News Summary

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord reiterated a “buy” rating and set a high $171 price target, signaling strong upside relative to the current level and supporting bullish investor thesis on long‑term mRNA opportunity. Canaccord reaffirms buy, $171 PT
• Positive Sentiment: Goldman Sachs reaffirmed its “buy” rating, providing another institutional vote of confidence that may stabilize sentiment among growth‑oriented holders. Goldman Sachs reaffirms buy
• Positive Sentiment: BioNTech and its co‑founders announced plans to pursue next‑generation mRNA innovations — a strategic signal that the company is investing in future product pipelines beyond COVID vaccines. Co‑founders pursue next‑gen mRNA
• Neutral Sentiment: Independent write‑ups are debating whether recent weakness makes BNTX a value play; the analysis highlights multi‑period share declines but leaves valuation conclusions to readers. Yahoo analysis on BNTX valuation
• Neutral Sentiment: Data feeds flagged a “large increase” in short interest, but the published figures are inconsistent (zeros/NaN and 0.0 days to cover), suggesting a likely reporting glitch rather than actionable short‑squeeze pressure.
• Neutral Sentiment: BMO trimmed its price target (to $128) but kept an “outperform” stance — a modest downgrade in optimism rather than a rout. BMO lowers PT to $128
• Negative Sentiment: Several outlets reported a steep share drop after an earnings miss and leadership changes (founder departures); that combination typically triggers near‑term selling and raises execution risk. Earnings miss & founder exodus — Blockonomi Earnings miss & leadership change — Tokenist
• Negative Sentiment: Multiple sell‑side revisions trimmed expectations: Citigroup lowered its PT to $130 (still a “buy”), TD Cowen cut to $94 and moved to “hold”, and Jefferies published more cautious forecasts — collectively cooling near‑term analyst enthusiasm. Citigroup cuts PT to $130 TD Cowen cuts to $94 Jefferies lowers expectations

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.